Identify. Benign lung nodules. No biopsy.
SmartLung Dx is a non-invasive blood test.
Complications
SmartLung Dx™, entering the final stage of development, is a blood-based assay intended for use as an adjunctive confirmatory test to assess the absence of lung cancer in patients with a history of smoking who have an imaging-detected nodule between 0.8 – 3.0 cm and who are being considered for a downstream invasive procedure.
Driving Healthcare Forward
- It is estimated that there are tens of millions of patients in the total addressable global market
- The current standard of care is an invasive lung biopsy, or watch-and-wait with multiple scans
- SmartLung Dx is a non-invasive blood test that aims to identify lung nodules that are likely benign, enabling patients to avoid potentially risky invasive biopsy procedures
- This test is designed to help minimize hospitalizations from lung biopsy complications